Mazindol: a risk factor for pulmonary arterial hypertension?
| Autor: | Christophe Delclaux, Elizabeth Hussey, Eric Konofal, Cherine Benzouid, Michel Lecendreux |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Hypertension Pulmonary 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Dopamine Risk Factors Internal medicine medicine Attention deficit hyperactivity disorder Humans Anorexic drugs Risk factor chemistry.chemical_classification Mazindol business.industry General Medicine medicine.disease Pulmonary hypertension chemistry Anesthesia Cardiology Central Nervous System Stimulants business 030217 neurology & neurosurgery Narcolepsy Tricyclic medicine.drug |
| Zdroj: | Sleep medicine. 34 |
| ISSN: | 1878-5506 |
| Popis: | Mazindol is an imidazo-isoindole derivative, a tricyclic compound and a non-amphetamine central nervous system stimulant that blocks dopamine and norepinephrine reuptake. Mazindol was withdrawn from the US and European markets in 1999 for reasons unrelated to its efficacy or safety around a time when other anorexic drugs were found to be associated with the development of pulmonary arterial hypertension (PAH). Despite the use of mazindol for decades, reports of PAH due to mazindol intake have been extremely rare. Recent interest on mazindol has emerged for the treatment of narcolepsy and attention-deficit/hyperactivity disorder. Therefore, an updated understanding of the potential benefits and risks of mazindol in these patient populations is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect